DNA Vaccine for Treating and Preventing Type 1 Diabetes
Summary
USPTO granted Patent US12589141B2 to The Fifth Medical Center of Chinese PLA General Hospital for a DNA vaccine using a B7-2-PE40 exotoxin fusion gene to treat Type 1 Diabetes. The patent, with 10 claims, covers reduction of blood glucose, restoration of insulin secretion, and reduction of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) levels. The application was filed on March 2, 2020.
What changed
The USPTO issued Patent US12589141B2 granting intellectual property protection for a DNA vaccine composition and method of use for treating and/or preventing Type 1 Diabetes. The invention comprises a recombinant nucleic acid construct containing the B7-2-PE40 exotoxin fusion gene, with claims covering reduction of blood glucose levels, restoration of endogenous insulin secretion, and decreased autoantibody markers (ICA and GAD). Assignee is The Fifth Medical Center of Chinese PLA General Hospital.
Patent grant announcements do not impose regulatory compliance obligations. Intellectual property and research teams should catalog this patent for prior art analysis, freedom-to-operate assessments, and potential licensing evaluation. No action is required for regulatory compliance purposes.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DNA vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof
Grant US12589141B2 Kind: B2 Mar 31, 2026
Assignee
The Fifth Medical Center of Chinese PLA General Hospital
Inventors
Yongzhi Xi, Song Yun
Abstract
Provided is use of a recombinant nucleic acid construct containing a B7-2-PE40 exotoxin fusion gene in the preparation of a DNA vaccine or medicament for treatment and/or prevention of type 1 diabetes. The DNA vaccine can reduce blood glucose in patient with type 1 diabetes, restore the secretion of insulin of the patients per se, and reduce the contents of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) in the patients.
CPC Classifications
A61K 2039/6037 A61K 2039/53 A61K 39/0008 A61K 39/0005 A61P 3/10 C07K 14/70532 C07K 2319/00 C07K 14/195 C12N 15/86
Filing Date
2020-03-02
Application No.
17767291
Claims
10
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.